These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 29968311)

  • 1. Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis.
    Rencz F; Gulácsi L; Péntek M; Poór AK; Sárdy M; Holló P; Szegedi A; Remenyik É; Brodszky V
    Br J Dermatol; 2018 Nov; 179(5):1102-1108. PubMed ID: 29968311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DLQI-R scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea.
    Rencz F; Gulácsi L; Péntek M; Szegedi A; Remenyik É; Bata-Csörgő Z; Bali G; Hidvégi B; Tamási B; Poór AK; Hajdu K; Holló P; Kinyó Á; Sárdy M; Brodszky V
    Br J Dermatol; 2020 May; 182(5):1167-1175. PubMed ID: 31419310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A detailed analysis of 'not relevant' responses on the DLQI in psoriasis: potential biases in treatment decisions.
    Rencz F; Poór AK; Péntek M; Holló P; Kárpáti S; Gulácsi L; Szegedi A; Remenyik É; Hidvégi B; Herszényi K; Jókai H; Beretzky Z; Brodszky V
    J Eur Acad Dermatol Venereol; 2018 May; 32(5):783-790. PubMed ID: 29114942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study.
    Imafuku S; Kanai Y; Murotani K; Nomura T; Ito K; Ohata C; Yamazaki F; Miyagi T; Takahashi H; Okubo Y; Saeki H; Honma M; Tada Y; Mabuchi T; Higashiyama M; Kobayashi S; Hashimoto Y; Seishima M; Kakuma T
    J Dermatol Sci; 2021 Mar; 101(3):185-193. PubMed ID: 33495058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Rasch model analysis of two interpretations of 'not relevant' responses on the Dermatology Life Quality Index (DLQI).
    Rencz F; Mitev AZ; Szabó Á; Beretzky Z; Poór AK; Holló P; Wikonkál N; Sárdy M; Kárpáti S; Szegedi A; Remenyik É; Brodszky V
    Qual Life Res; 2021 Aug; 30(8):2375-2386. PubMed ID: 33683650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the Frequency of "Not Relevant" Responses on the Dermatology Life Quality Index by Sociodemographic Characteristics of Patients With Psoriasis.
    Barbieri JS; Shin DB; Syed MN; Takeshita J; Gelfand JM
    JAMA Dermatol; 2020 Apr; 156(4):446-450. PubMed ID: 32101261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register.
    Hjalte F; Carlsson KS; Schmitt-Egenolf M
    Br J Dermatol; 2018 Jan; 178(1):245-252. PubMed ID: 28644904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.
    Davison NJ; Thompson AJ; Turner AJ; Longworth L; McElhone K; Griffiths CEM; Payne K;
    Value Health; 2018 Aug; 21(8):1010-1018. PubMed ID: 30098665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary.
    Herédi E; Rencz F; Balogh O; Gulácsi L; Herszényi K; Holló P; Jókai H; Kárpáti S; Péntek M; Remenyik É; Szegedi A; Brodszky V
    Eur J Health Econ; 2014 May; 15 Suppl 1():S111-9. PubMed ID: 24832842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study.
    Chaptini C; Quinn S; Marshman G
    Australas J Dermatol; 2016 Aug; 57(3):e72-5. PubMed ID: 26010650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Assessment of health-related quality of life in psoriasis patients in Hungary].
    Poór AK; Sárdy M; Cserni T; Brodszky V; Holló P; Gulácsi L; Remenyik É; Szegedi A; Rencz F; Péntek M
    Orv Hetil; 2018 May; 159(21):837-846. PubMed ID: 29779387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis.
    Zidane M; Dressler C; Gaskins M; Nast A
    JAMA Dermatol; 2019 Dec; 155(12):1380-1389. PubMed ID: 31617856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients.
    Poór AK; Rencz F; Brodszky V; Gulácsi L; Beretzky Z; Hidvégi B; Holló P; Kárpáti S; Péntek M
    Qual Life Res; 2017 Dec; 26(12):3409-3419. PubMed ID: 28875430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the Dermatology Life Quality Index (DLQI) underestimate the disease-specific burden of psoriasis patients?
    Langenbruch A; Radtke MA; Gutknecht M; Augustin M
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):123-127. PubMed ID: 30160802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation and application of the Dermatology Life Quality Index score, a modification of the DLQI score, in psoriasis patients.
    Zou Q; Luo Y; Hao D; Li M; Jihui C
    J Health Popul Nutr; 2024 Jun; 43(1):92. PubMed ID: 38909238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis.
    Pickard AS; Gooderham M; Hartz S; Nicolay C
    J Med Econ; 2017 Jan; 20(1):19-27. PubMed ID: 27471948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the DLQI appropriate for medical decision-making in psoriasis patients?
    Poór AK; Brodszky V; Péntek M; Gulácsi L; Ruzsa G; Hidvégi B; Holló P; Kárpáti S; Sárdy M; Rencz F
    Arch Dermatol Res; 2018 Jan; 310(1):47-55. PubMed ID: 29128966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies.
    Mattei PL; Corey KC; Kimball AB
    J Eur Acad Dermatol Venereol; 2014 Mar; 28(3):333-7. PubMed ID: 23425140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management.
    Augustin M; Langenbruch A; Gutknecht M; Reich K; Körber A; Maaßen D; Mrowietz U; Thaçi D; von Kiedrowski R; Radtke MA
    Br J Dermatol; 2018 Dec; 179(6):1385-1391. PubMed ID: 30334253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Life quality among psoriasis patients based on Dermatology Life Quality Index evaluation and its association with psoriasis severity in China: a cross-sectional study.
    Chen Y; Wei L; Song Y; Zhang R; Kuai L; Li B; Wang R
    Ann Med; 2023 Dec; 55(1):2231847. PubMed ID: 37417705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.